Treatment with Huntexil (pridopidine) can slow the decline in total functional capacity in people with Huntington’s disease, a new analysis of clinical trial data indicate. The findings were published in the Journal of Huntington’s Disease, in two studies: “Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study” and “Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.” Huntexil is…

You must be logged in to read/download the full post.